Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 177lu-dota-hh1
2. 177lu-tetraxetan-tetulomab
3. 177lu-tetulomab
4. Betalutin
5. Tetulomab Tetraxetan Lu-177
1. 177lu-tetraxetan-hh1
2. 177lu-dota-hh1
3. Unii-054zp16k2q
4. 054zp16k2q
5. Who 10078
6. Lutetium (lu177) Lilotomab Satetraxetan
7. Lutetium (177lu) Lilotomab Satetraxetan [inn]
8. Lutetium (lu177) Lilotomab Satetraxetan [usan]
9. 1453362-90-7
10. Immunoglobulin G1-kappa, Anti-(homo Sapiens Cd37 (tspan26, Tetraspanin-26)), Mus Musculus Monoclonal Antibody, Lutetium (lu 177) Radiolabelled Satetraxetan (dota Derivative) Conjugate
| Molecular Weight | 871.7 g/mol |
|---|---|
| Molecular Formula | C30H44LuN7O10S |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 16 |
| Rotatable Bond Count | 12 |
| Exact Mass | 871.23080 g/mol |
| Monoisotopic Mass | 871.23080 g/mol |
| Topological Polar Surface Area | 296 Ų |
| Heavy Atom Count | 49 |
| Formal Charge | 0 |
| Complexity | 1050 |
| Isotope Atom Count | 1 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 4 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A 177Lu Lilotomab Satetraxetan manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of 177Lu Lilotomab Satetraxetan, including repackagers and relabelers. The FDA regulates 177Lu Lilotomab Satetraxetan manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. 177Lu Lilotomab Satetraxetan API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A 177Lu Lilotomab Satetraxetan supplier is an individual or a company that provides 177Lu Lilotomab Satetraxetan active pharmaceutical ingredient (API) or 177Lu Lilotomab Satetraxetan finished formulations upon request. The 177Lu Lilotomab Satetraxetan suppliers may include 177Lu Lilotomab Satetraxetan API manufacturers, exporters, distributors and traders.
177Lu Lilotomab Satetraxetan Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of 177Lu Lilotomab Satetraxetan GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right 177Lu Lilotomab Satetraxetan GMP manufacturer or 177Lu Lilotomab Satetraxetan GMP API supplier for your needs.
A 177Lu Lilotomab Satetraxetan CoA (Certificate of Analysis) is a formal document that attests to 177Lu Lilotomab Satetraxetan's compliance with 177Lu Lilotomab Satetraxetan specifications and serves as a tool for batch-level quality control.
177Lu Lilotomab Satetraxetan CoA mostly includes findings from lab analyses of a specific batch. For each 177Lu Lilotomab Satetraxetan CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
177Lu Lilotomab Satetraxetan may be tested according to a variety of international standards, such as European Pharmacopoeia (177Lu Lilotomab Satetraxetan EP), 177Lu Lilotomab Satetraxetan JP (Japanese Pharmacopeia) and the US Pharmacopoeia (177Lu Lilotomab Satetraxetan USP).
LOOKING FOR A SUPPLIER?
